Not available
Quote | REGENXBIO Inc. (NASDAQ:RGNX)
Last: | $13.50 |
---|---|
Change Percent: | 0.7% |
Open: | $12.68 |
Close: | $13.50 |
High: | $13.69 |
Low: | $12.35 |
Volume: | 545,254 |
Last Trade Date Time: | 07/23/2024 03:00:00 am |
News | REGENXBIO Inc. (NASDAQ:RGNX)
2024-07-23 11:47:46 ET Summary Today, we take a more in-depth look at small-cap biopharma Ocular Therapeutix, Inc. The company is focused on developing therapies for eye conditions using bioresorbable hydrogel-based technology. Ocular's lead clinical candidate, Axpaxli, is und...
2024-07-04 04:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Message Board Posts | REGENXBIO Inc. (NASDAQ:RGNX)
Subject | By | Source | When |
---|---|---|---|
36M share trading float. | crudeoil24 | investorshub | 09/13/2021 11:36:55 AM |
AbbVie And REGENXBIO Announce Eye Care Collaboration; AbbVie | crudeoil24 | investorshub | 09/13/2021 11:27:19 AM |
https://www.google.com/amp/s/www.nasdaq.com/article/4-gene-therapy-players-likel | StockLearner2011 | investorshub | 06/03/2019 1:00:24 PM |
I believe the buyout is in a distance | StockLearner2011 | investorshub | 05/31/2019 12:31:48 PM |
is there an argument for a BO? https://msmoneymoves.com/2019/05/28/could-this-bi | Zmill | investorshub | 05/29/2019 1:41:40 AM |
News, Short Squeeze, Breakout and More Instantly...
2024-07-04 04:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients PR Newswire Company to begin enrollment of patients aged 1-3 years Expects data from younger cohort to be part of pivotal plans and BLA filing for broad lab...
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II PR Newswire Aligned with FDA on content of BLA and plans for submission: Submission of a rolling BLA using the accelerated approval...